Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells

BACKGROUND: Dovitinib (TKI-258) is a receptor tyrosine kinase (RTK) inhibitor targeting fibroblast growth factor receptor (FGFR) and further related RTKs. TKI-258 is under investigation as anticancer drug for the treatment of various cancers including bladder cancer with aberrant RTK signaling. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Hänze, Jörg, Henrici, Marcus, Hegele, Axel, Hofmann, Rainer, Olbert, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866461/
https://www.ncbi.nlm.nih.gov/pubmed/24325461
http://dx.doi.org/10.1186/1471-2407-13-589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866461/
https://www.ncbi.nlm.nih.gov/pubmed/24325461
http://dx.doi.org/10.1186/1471-2407-13-589

Ejemplares similares